H
H. Henary
Researcher at Amgen
Publications - 31
Citations - 3221
H. Henary is an academic researcher from Amgen. The author has contributed to research in topics: KRAS & Viral Oncogene. The author has an hindex of 12, co-authored 29 publications receiving 1358 citations. Previous affiliations of H. Henary include University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon,Karen Rex,Anne Y. Saiki,Christopher Mohr,Keegan Cooke,Dhanashri Bagal,Kevin Gaida,Tyler Holt,Charles G. Knutson,Neelima Koppada,Brian A. Lanman,Jonathan Werner,Aaron S. Rapaport,Tisha San Miguel,Roberto Ortiz,Roberto Ortiz,Tao Osgood,Ji Rong Sun,Xiaochun Zhu,Xiaochun Zhu,John D. McCarter,Laurie P. Volak,Laurie P. Volak,Brett E. Houk,Marwan Fakih,Bert H. O'Neil,Timothy J. Price,Gerald Steven Falchook,Jayesh Desai,James Kuo,Ramaswamy Govindan,David S. Hong,Wenjun Ouyang,H. Henary,Tara Arvedson,Victor J. Cee,J. Russell Lipford +36 more
TL;DR: Treatment of KRASG 12C-mutant cancer cells with the KRAS(G12C) inhibitor AMG 510 leads to durable response in mice, and anti-tumour activity in patients suggests that AMG510 could be effective in patients for whom treatments are currently lacking.
Journal ArticleDOI
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.
David S. Hong,Marwan Fakih,John H. Strickler,Jayesh Desai,G. Durm,Geoffrey I. Shapiro,Gerald S. Falchook,Timothy J. Price,Adrian G. Sacher,Crystal S. Denlinger,Yung-Jue Bang,Grace K. Dy,John C. Krauss,Yasutoshi Kuboki,James Kuo,Andrew L. Coveler,Keunchil Park,Tae Won Kim,Fabrice Barlesi,Pamela N. Munster,Suresh S. Ramalingam,Timothy F. Burns,Funda Meric-Bernstam,H. Henary,J. Ngang,Gataree Ngarmchamnanrith,J. Kim,Brett E. Houk,Jude Canon,J. Russell Lipford,Gregory Friberg,Piro Lito,Ramaswamy Govindan,Bob T. Li +33 more
TL;DR: Sotorasib showed encouraging anticancer activity in patients with heavily pretreated advanced solid tumors harboring the KRAS p.G12C mutation and responded to pharmacokinetics and objective response according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.
Journal ArticleDOI
Sotorasib for Lung Cancers with KRAS p.G12C Mutation.
Ferdinandos Skoulidis,Bob T. Li,Grace K. Dy,Timothy J. Price,Gerald Steven Falchook,Jürgen Wolf,Antoine Italiano,Martin Schuler,Martin Schuler,Hossein Borghaei,Fabrice Barlesi,Terufumi Kato,Alessandra Curioni-Fontecedro,Adrian G. Sacher,Alexander I. Spira,Suresh S. Ramalingam,Toshiaki Takahashi,Benjamin Besse,Abraham Anderson,Agnes Ang,Qui Tran,Omar Mather,H. Henary,Gataree Ngarmchamnanrith,Gregory Friberg,Vamsidhar Velcheti,Ramaswamy Govindan +26 more
TL;DR: Sotorasib showed anticancer activity in patients with KRAS p.G12C-mutated advanced solid tumors in a phase 1 study as discussed by the authors, and particularly promising anti-cancer activity was observed i...
Journal ArticleDOI
Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.
Marwan Fakih,Bert H. O'Neil,Timothy J. Price,Gerald Steven Falchook,Jayesh Desai,James Kuo,Ramaswamy Govindan,Erik Rasmussen,Phuong Khanh Morrow,J. Ngang,H. Henary,David S. Hong +11 more
TL;DR: The KRASG12C mutation is found in approximately 13% of lung adenocarcinomas and 1–3% of other solid tumors, but there is no approved therapy that targets this mutation, and AMG 510 is a potential new drug candidate.
Journal ArticleDOI
Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia
Harry P. Erba,Pamela S. Becker,Pamela S. Becker,Paul J. Shami,Michael R. Grunwald,Donna L. Flesher,Min Zhu,Erik Rasmussen,H. Henary,Abraham Anderson,Eunice S. Wang +10 more
TL;DR: AMG 232 was associated with gastrointestinal AEs at higher doses but had acceptable pharmacokinetics, on-target effects, and promising clinical activity warranting further investigation in patients with relapsed/refractory acute myeloid leukemia.